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This editorial refers to ‘Effect of statins on ventricular
tachyarrhythmia, cardiac arrest, and sudden cardiac death:
a meta-analysis of published and unpublished evidence
from randomized trials’†, by K. Rahimi et al., on page 1571
Statins are undoubtedly the mainstay in the treatment of hyperlip-
idaemia. They are used in primary and secondary prevention of
cardiovascular disease.1,2 It is therefore not surprising that statins
rank very high among the most successful drugs in the history of
medicine. For example, atorvastatin has raked in around US$130
billion for Pfizer during its 14 years on the market, making it cur-
rently the world’s bestselling drug.3
Recent studies show that statins possess powerful pleiotropic
effects that are independent of their effects on lipids and
lipoproteins.4 The pleiotropic effects of statins are credited
to several processes that result from the inhibition of
hydroxy-methyl-glutaryl-CoA (HMGCoA) reductase. The main
effect of the drugs is the inhibition of cholesterol and isoprenoid syn-
thesis, which results ultimately in the up-regulation of endothelial
nitric oxide synthase, an enzyme involved in vascular endothelial
function. The inhibition of isoprenoid formation also leads to antioxi-
dant effects. Additionally, inflammatory markers such as C-reactive
protein and nuclear factor-kB have been shown to be reduced by
statins, leading to the hypothesis that statins possess anti-
inflammatory properties.Other proposedmechanisms for the pleio-
tropic effects of statins include immunomodulation, normalization of
sympathetic outflow, plaque stabilization, decreased activationof the
blood coagulation cascade, and inhibition of platelet aggregation.4
Pathophysiologically, mechanisms such as statin-induced plaque
stabilization, changes to the transmembrane ion channel conduc-
tion, antioxidant and antiproliferative effects, and a decrease in
the parasympathetic tone may potentially account for an antiar-
rhythmic effect of statin therapy which would at least be partially
independent of the proven antiatherogenic effects of statin
therapy.5 In fact, the use of statins has been suggested to protect
against various arrythmic disorders,6,7 and a meta-analysis pub-
lished in 2008 reported a significant reduction in the incidence
or recurrence of atrial fibrillation in patients in sinus rhythm
using statins.8 However, in a more comprehensive collaborative
meta-analysis of published and unpublished evidence from rando-
mized controlled trials, the suggested beneficial effect of statins
on atrial fibrillation was clearly not supported.9
What about the effect of statin treatment on ventricular arrhythmic
complications? A very recent meta-analysis suggested that statins
reduce the risk of ventricular tachyarrhythmia in patients with coron-
ary artery disease or non-ischaemic cardiomyopathy by about
one-third.10 Rahimi et al. have now contradicted this finding.11 In
their meta-analysis of 29 trials with 113 568 participants comparing
statin vs. a control, statin therapy did not significantly reduce the
risk of ventricular tachyarrhythmia or cardiac arrest. Although the
use of statins was associated with a significant 10% reduction of
sudden cardiac death, a beneficial direct antiarrhythmic effect inde-
pendent of the antiatherogenic effect of statin therapy seems very un-
likely. Recently, a large autopsy series reported that coronary artery
disease was responsible for sudden cardiac death in 37% of deaths
in the group of those aged 21–30, and in up to 80% of deaths in
the group of those aged 31–40.12 When taking into account that
statin therapy reduced other (non-sudden) cardiac deaths in included
trials by 20%, an antiarrhythmic beneficial effect of statins indepen-
dendent of their antiatherogenic properties seems unlikely to account
for the observed reduction in sudden cardiac death.
How can the discrepant findings of statin therapy on the occur-
rence of ventricular arrhythmias between these two recent
meta-analyses be explained? A closer look at the two meta-analyses
may help in resolving the apparent conflicting evidence. Both
meta-analyses do not report substantial evidence of heterogeneity
and both report a low likelihood of publication bias. However, the
absence of heterogeneity and the low likelihood of publication bias
exclude only two of many more potential pitfalls of meta-analyses
leading to spurious conclusions. Of the nine identified prospective
studies with a total of 150 953 individuals in the meta-analysis by
Wanahita et al.,10 only two were randomized controlled trials
which together included ,1000 individuals. All the other studies
were observational, with one of these studies contributing 99%
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of all individuals included in the analysis. By using a more comprehen-
sive literature search and by undertaking the effort to contact authors
of large statin trials to contribute collected, but previously unpub-
lished data on the incidence of ventricular arrhythmias, Rahimi
et al.11 identified 29 randomized controlled trials comparing statin
with control with 113 568 individuals, .100 times more individuals
than in the two randomized controlled trials identified by Wanahita
et al.10 In addition,Wanahita et al. did not conduct a formal critical ap-
praisal of the quality of included studies and failed to report an assess-
ment of the risk of bias in included studies as recommended by the
PRISMA statement.13 For these reasons, the results of the
meta-analysis byWanahita et al.10 can only be regarded as hypothesis
generating. Rahimi et al.,11 by restricting their meta-analysis to rando-
mized controlled trials and collecting all available published and un-
published data about the effects of statins on the risk of ventricular
arrhythmias, now demonstrate that an antiarrhytmic effect of
statins is highly unlikely.
Nowadays, clinicians quite often are faced with seemingly con-
flicting evidence from the medical literature. This may lead to un-
certainty in clinical decision-making, especially for busy clinicians
with time constraints not allowing them to read and analyse
medical articles more in depth and focusing on abstracts only. In
order to avoid misleading conclusions from abstracts of
meta-analyses, all medical journals should adhere to the reporting
guidelines as formulated in the PRISMA statement13 that requires a
structured abstract with an appraisal of the included studies as well
as a description of the limitations of the meta-analysis.
The meta-analysis by Rahimi et al.11 represents the currently
best available evidence on the effect of statin therapy on ventricu-
lar arrhythmias and demonstrates clearly that statin therapy is
highly unlikely to have a beneficial effect for the prevention of ven-
tricular arrhythmias. Statins may still possess many pleiotropic
effects, but independent antiarrhythmic effects do not seem to
figure amongst them.
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